- Home
- ENSC vs CWD Comparison
ENSC vs CWD Comparison
Compare ENSC & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- CWD
- Stock Information
- Founded
- ENSC 2003
- CWD 2009
- Country
- ENSC United States
- CWD United States
- Employees
- ENSC N/A
- CWD N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- CWD Real Estate
- Sector
- ENSC Health Care
- CWD Finance
- Exchange
- ENSC Nasdaq
- CWD Nasdaq
- Market Cap
- ENSC 5.5M
- CWD 4.5M
- IPO Year
- ENSC N/A
- CWD 2023
- Fundamental
- Price
- ENSC $2.13
- CWD $2.91
- Analyst Decision
- ENSC
- CWD
- Analyst Count
- ENSC 0
- CWD 0
- Target Price
- ENSC N/A
- CWD N/A
- AVG Volume (30 Days)
- ENSC 84.7K
- CWD 39.7K
- Earning Date
- ENSC 08-13-2025
- CWD 08-11-2025
- Dividend Yield
- ENSC N/A
- CWD N/A
- EPS Growth
- ENSC N/A
- CWD N/A
- EPS
- ENSC N/A
- CWD N/A
- Revenue
- ENSC $6,224,081.00
- CWD $35,429,000.00
- Revenue This Year
- ENSC N/A
- CWD N/A
- Revenue Next Year
- ENSC $1,381.48
- CWD $31.12
- P/E Ratio
- ENSC N/A
- CWD N/A
- Revenue Growth
- ENSC 256.35
- CWD N/A
- 52 Week Low
- ENSC $1.62
- CWD $2.61
- 52 Week High
- ENSC $14.67
- CWD $16.00
- Technical
- Relative Strength Index (RSI)
- ENSC 45.62
- CWD 40.02
- Support Level
- ENSC $1.97
- CWD $2.61
- Resistance Level
- ENSC $2.40
- CWD $3.63
- Average True Range (ATR)
- ENSC 0.17
- CWD 0.32
- MACD
- ENSC -0.00
- CWD -0.00
- Stochastic Oscillator
- ENSC 37.21
- CWD 26.32
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.